Background
1. An urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations in the legs 2. Unpleasant sensations or the urge to move begin or worsen during periods of rest or inactivity such as lying or sitting 3. Unpleasant sensations or the urge to move are partly or totally relieved by movement such as walking, bending, stretching, et cetera, at least as long as the activity continues 4. Unpleasant sensations or the urge to move are worse in the evening or at night than during the day, or only occur in the evening or night RLS varies in symptom severity ‡ and frequency. Mild RLS may cause minor annoyance, but severe RLS can negatively affect work, social activities, and function. RLS-induced sleep deprivation and daytime fatigue are common reasons RLS patients seek treatment. Severe RLS can be a chronic progressive disorder that may require long-term treatment.
Prevalence estimates for RLS in the United States range from 1.5 to 7.4 percent in adults. The variation reflects different approaches to diagnosing RLS and defining its frequency and severity. The etiology of primary RLS is unknown, but the disorder might occur secondary to other conditions such as iron deficiency, endstage renal disease, and pregnancy. Insufficient sleep and sleep disorders such as sleep apnea might exacerbate symptoms of RLS.
Treatment options for RLS include nonpharmacologic and pharmacologic strategies. Nonpharmacologic treatment approaches include pneumatic compression devices, nearinfrared light therapy, lower body resistance exercise, and using botanical preparations. The major classes of pharmacologic agents used are listed in Table 1 . The choice of pharmacologic agent used to treat RLS depends on the frequency and severity of symptoms.
Dopaminergic agents can result in a treatment complication called augmentation. Augmentation is a drug-induced exacerbation of symptoms characterized by greater symptom intensity, onset earlier in the day, and shorter latency during inactivity. With augmentation, symptoms may also spread to the arms, trunk, and face. Recent studies suggest augmentation is more likely to occur with levodopa when compared with dopamine agonists. Augmentation can lead to poorer outcomes, a switch to other classes of medication, or treatment discontinuation. 1, 2 Augmentation is usually considered as resolved when the medication triggering augmentation has been discontinued or when the patient has been switched to another medication.
1,2
Clinicians face uncertainty related to defining RLS, assessing disease severity, and evaluating the risks and benefits of treatment. While these challenges apply to both primary care and specialty settings, they may be more pronounced in primary care. In response to a request from the public, a review was undertaken to evaluate the evidence regarding the potential benefits and adverse effects associated with various treatments for restless legs syndrome (RLS). This review did not cover other sleep disorders such as periodic limb movement disorder. The systematic review included 53 reports of randomized clinical trials and observational studies published through June 2012. The online version of this summary and the full report are available at www.effectivehealthcare.ahrq.gov/restless-legs.cfm. This summary is provided to inform discussions with patients of options and to assist in decisionmaking along with consideration of a patient's values and preferences. However, reviews of evidence should not be construed to represent clinical recommendations or guidelines. Gabapentin enacarbil also improved sleep adequacy based on the sleep adequacy domain of the MOS-SPI-II Scale.
Clinician Research Summary

Iron therapy
Results from one small, good-quality study † showed that, when compared with placebo, intravenous ferric carboxymaltose:
Slightly improved symptom scores on the IRLS Rating Scale
Slightly improved RLS quality of life Slightly improved patient-reported sleep outcomes Two small randomized trials of iron therapy (one intravenous and one oral) versus placebo in adults with iron deficiency suggested that iron may improve both the percentage of adults considered IRLS responders and symptom scores on the IRLS Rating Scale.** (Continued in the next column)
Evidence of Benefits (Continued)
Opioids and hypnotics
No eligible studies assessed opioids or sedative hypnotics, though these are sometimes used clinically for RLS treatment.
Nonpharmacologic interventions
Pneumatic compression devices reduced IRLS Rating Scale symptom scores more than sham. Near-infrared light treatment improved IRLS Rating Scale symptom, scores more than sham. Strength training and treadmill walking improved IRLS symptoms but adherence was poor. The botanical extract valerian was not effective in treating RLS.
(Continued with footnotes on the next page)
When compared with placebo, dopamine agonists and alpha-2-delta ligands reduce RLS symptoms and improve patient-reported sleep outcomes and disease-specific quality of life. Moderate-level evidence suggests benefits of intravenous iron on symptoms of RLS. No eligible studies assessed opioids or sedative hypnotics as treatment for RLS. These agents also have potentially serious adverse effects. Some nonpharmacologic interventions such as compression stockings, near-infrared light, or exercise improve RLS symptoms (evidence level low to moderate). Adverse effects of pharmacologic therapies and long-term treatment withdrawals due to adverse effects or lack of efficacy are common. Evidence from observational studies suggests that augmentation is common across dopaminergic agents. The studies included in this review were conducted in adults with moderate to severe RLS. The long-term effectiveness and applicability of the assessed RLS therapies for adults with milder or less frequent RLS symptoms, individuals with secondary RLS, and children are unknown.
Strength of Evidence Scale
High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect. Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low: Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
Insufficient: Evidence is either unavailable or does not permit a conclusion.
Rating Scales Used To Evaluate Patient Outcomes
The International RLS (IRLS) Rating Scale is a 10-item scale where items such as intensity, frequency, and consequences of RLS are rated by patient and investigator on a 5-point scale to give a global score ranging from 0 (no RLS) to 40 (very severe RLS). Clinically meaningful responder criteria are the resolution of symptoms (score = 0); the percentage of patients with reduction of symptoms from very severe or severe to moderate or mild; and a 50-percent or greater change in the score from baseline.
The Clinical Global Impressions (CGI) or Patient Global Impressions (PGI) Scale has individual items such as disease severity, improvement from baseline, therapeutic effect, and side effects from treatment. Items are rated on a 7-point scale. Scores are not combined; often just one component of the scale (e.g., improvement) is assessed by the clinician (CGI) or the patient. Clinically meaningful responder criteria are the percentages of patients who are much improved or very much improved on the CGI Scale or the PGI Scale.
The RSL Quality of Life (RLS-QoL) Scale is an 18-item scale where items such as daily function, social activities and travel arrangements, morning activities and concentration, and sleep and sexual activity are rated on a 5-point scale to give a global score.
The Medical Outcomes Study-Sleep Problem Index II (MOS-SPI-II)
Scale is a 12-item scale where several aspects of sleep such as sleep initiation, maintenance, quantity, quality, sleep adequacy, and daytime somnolence are rated by the patient.
Clinical Bottom Line (Continued)
Evidence of Harms
Dopamine agonists (ropinirole, pramipexole, and rotigotine) Dopamine agonists were associated with more adverse effects than placebo.
Study withdrawals due to adverse effects were more common with dopamine agonists than with placebo. The differences were mainly due to adverse effect-related withdrawals reported in studies of transdermal rotigotine.
More patients randomized to a dopamine agonist had at least one adverse effect when compared with placebo.
Short-term adverse effects from dopamine agonist treatment included nausea, vomiting, somnolence, and fatigue.
Evidence from observational studies suggests that augmentation is common across dopaminergic agents (dopamine agonists and levodopa), with prevalence estimates ranging from 2.3 to 60 percent. The reason for the wide variation in prevalence estimates across drugs is unclear. † † (Continued in the next column)
Evidence of Harms (Continued)
Alpha-2-delta ligands (gabapentin enacarbil and pregabalin) Alpha-2-delta ligands were associated with more adverse effects than placebo.
More patients randomized to alpha-2-delta ligands had at least one adverse effect when compared with placebo.
Somnolence, unsteadiness or dizziness, and dry mouth were much more common with alpha-2-delta ligands than with placebo.
Study withdrawals (due to any reason) were less common with alpha-2-delta ligands than with placebo.
* These are patients with a greater than 50-percent reduction in symptom scores on the IRLS Rating Scale or who were "improved" or "much improved" on the CGI Scale or the PGI Scale. † Serum ferritin levels were 26.8 mcg/L for females and 63.6 mcg/L for males among patients included in this trial. ** In the trial evaluating intravenous iron, serum ferritin levels were reported to be 20.55 mcg/L in the included patients. Serum ferritin levels were not reported in the trial evaluating oral iron therapy. † † This finding was not rated. 
